You are here

Home » Content

Sıçanlarda Pilocarpin ile Oluşturulan Epilepside Topiramatın Nöronlar Üzerine Etkisi

The Effect of Topiramate on Neurons in Epilepsy which is Created with Pilocarpin in Rats

Journal Name:

  • Uludag University Journal of The Faculty of Veterinary Medicine

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Seizures are common and are treated in all branches of medicine. Approximately 2% of people will have one or more seizures during their life. Epilepsy, a nervous system disorder that occurs as a result of the neurons in the brain of the sudden, excessive and irregular discharge. Unpredictable irregularities can be seen in consciousness, behavior and motor activity. Epilepsy as well as in human medicine has an important place in veterinary medicine. Epilepsy is a disease that reduce quality of life of animals. Topiramate is one of several newer antiepileptic drugs that were introduced in the 1990s. Although the mechanism of action of TPM is not fully understood, it has a number of mechanisms of action including inhibition of glutamate activity via on α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate receptors. It is considered as a neuroprotective agent following seizures. Due to its activity on different receptors, the possible effects of TPM in the treatment of epilepsy and different disorders still have been the subject of many studies. In this study, we aimed to investigate the neuroprotective effect of the topiramate treatment on neurons in experimental epilepsy which is created with pilocarpine. Another aim of this study also TPM and other newgeneration antiepileptic drugs increasing usage and contribute to the advantages highlighted in veterinary medicine. TPM is not yet used as therapeutically in veterinary medicine. This study may serve as an initial reference for future studies on treatment of epilepsy in veterinary medicine.
Bookmark/Search this post with
Abstract (Original Language): 
Nöbetler tıbbın bütün alanlarında karşımıza çıkan, oldukça sık görülen bir durumdur. İnsanların yaklaşık % 2’si yaşamları boyunca bir veya daha fazla sayıda nöbet geçirmişlerdir. Epilepsi, beyindeki nöronların ani, aşırı ve düzensiz deşarjları sonucu meydana gelen sinir sistemi rahatsızlığıdır. Bilinç, davranış ve motor aktivitelerde önceden tahmin edilemeyen düzensizlikler görülebilmektedir. İnsan hekimliğinde olduğu kadar veteriner hekimlikte de epilepsi önemli bir yer tutar. Hayvanların yaşam kalitesini düşüren bir hastalıktır. Topiramat (TPM), 1990’lı yıllarda üretilen birkaç yeni antiepileptik ilaçtan biridir. TPM’nin etki mekanizması tam olarak anlaşılamamış olmasına rağmen, çok sayıda etki mekanizmasına sahiptir. Bunlardan birisi α-amino-3- hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) ve kainat reseptörleri yoluyla glutamat aktivitesinin inhibisyonudur ve nöbetleri takiben nöroprotektif ajan olarak değerlendirilir. Farklı reseptörler üzerine etki etmesi nedeniyle epilepsi ve farklı hastalıkların tedavisinde TPM’nin muhtemel etkisi hala pek çok çalışmaya konu olmaktadır. Bu çalışmada pilokarpinle oluşturulan deneysel epilepside, TPM tedavisinin, nöronlar üzerine olan nöroprotektif etkisinin araştırılması amaçlanmıştır. Ayrıca bu çalışmanın yapılmasının bir diğer amacı da veteriner hekimlikte TPM ve onun gibi diğer yeni kuşak antiepileptiklerin kullanımının arttırılması ve avantajlarının vurgulanmasına katkıda bulunmaktır. TPM veteriner hekimlikte tedavi amaçlı olarak henüz kullanılmamaktadır. Bu çalışma hayvan sağlığı alanında, epilepsinin tedavisinde TPM kullanılması açısından yeni bir başlangıç olabilir.
FULL TEXT (PDF): 
PDF icon arastirmax-sicanlarda-pilocarpin-ile-olusturulan-epilepside-topiramatin-noronlar-uzerine-etkisi.pdf
  • 2
1
7
  • Turkish

REFERENCES

References: 

1- Ak Sonat, F., 2009. Hayvanlarda Epilepsi. U. Ü.
Vet. Fak. Derg., 28, 47-52.
2- Ak Sonat, F., 2009. Antiepileptikler ve Yeni Bir
Antiepileptik Olan Topiramatın Epilepsi Tedavisindeki
Yeri ve Önemi. Kafkas Univ. Vet. Fak.
Derg., 15, 987-992.
3- Ak Sonat, F., Ercan, İ., Turan Özdemir, S.,
Özkaya, G., Noyan, B., 2009. Statistical shape
analysis of the rat hippocampus in epilepsia,
Anat. Sci. Int., 84, 298-304.
4. Alves, O.L., Doyle, A.J., Clausen, T., Gilman, C.,
Bullock, R., 2003. Evaluation of topiramate
neuroprotective effect in severe TBI using
microdalysis. Ann. N. Y. Acad. Sci., 993, 25-34.
5. Borowicz, K.K., Luszczki, J.J., Duda, A.M.,
Czuczwar, S.J., 2003. Effect of topiramate on the
anticonvulsant activity of conventional
antiepileptic drugs in two models of experimental
epilepsy. Epilepsia, 44, 640-646.
6. Bourgeois, B.F., 1996. New antiepileptic drugs.
Curr. Opin. Pediatr., 8, 543-548.
7. Cha, B.H., Silveira, D.C., Liu, X., Hu, Y.,
Holmes, G.L., 2002. Effect of topiramate
following recurrent and prolonged seizures
during early development. Epilepsy Res., 51,
217-232.
8. Czapinski, P., Blaszczyk, B., Czuczwar, S.J.,
2005. Mechanisms of action of antiepileptic
drugs. Curr. Top. Med. Chem., 5, 3-14.
9. Fisher, A., Wang, X., Cock, H.R., Thom M.,
Patsalos P.N., Walker, M.C., 2004. Synergism
between topiramate and budipine in refractory
status epilepticus in the rat. Epilepsia, 45, 1300-
1307.
10. Gibss, J.W., Sombati, S., Delorenzo, R.J.,
Coulter, D.A., 2000. Cellular actions of
topiramate: blockade of kainate evoked inward
currents in cultured hippocampal neurons.
Epilepsia, 41, 10-16.
11. Glauser, T., 1999. Topiramate. Epilepsia, 40, 71-
80.
12. Johannessen, S., Graw, L., Sıllanpaa, M.,
Tomson, T., 1995. Intractable Epilepsy,
Wrightson Biomedical Publishing Ltd.
13. Kaminski, R.M., Banerjee, M., Rogawski, M.A.,
2004. Topiramate selectively protects against
seizures induced by ATPA, a GluR5 kainate
receptor agonist. Neuropharmacology, 46, 1097-
1104.
14. Kanda, T., Kurokawa, M., Tamura, S.,
Nakamura, J., Ishii, A., Kuwana, Y., Serikawa,
T., Yamada, J., Ishihara, K., Sasa, M., 1996.
Topiramate reduces abnormally high
extracellular levels of glutamate and aspartate in
the hippocampus of spontaneously epileptic rats
(SER). Life Sci., 59, 1607-1616.
15. Karamustafalıoğlu, O., Demirkıran, S., 2004.
Psikiyatrik bozukluklarda topiramat kullanımı.
Klin. Psikofarm. Bült., 14, 26-37.
16. Koh, S., Jensen, F.E., 2001. Topiramate blocks
perinatal hypoxia-induced seizures in rat pups.
Ann. Neurol., 50, 366-372.
17. Kudin, A.P., Debska-Vielhaber, G., Vielhaber,
S., Elger, C.E., Kunz, W.S., 2004. The
mechanism of neuroprotection by topiramate in
an animal model of epilepsy. Epilepsia, 45, 1478-
1487.
18. Lee, S.R., Kim, D.P., Kim, J.E., 2000. Protective
effect of topiramate against hippocampal
neuronal damage after global ischemia in the
gerbils. Neurosci. Lett., 281, 183-186.
19. Macdonald, R.L., Kelly, K.M., 1995.
Antiepileptic drug mechanisms of action.
Epilepsia, 36, 2-12.
20. Nakamura, J., Tamura, S., Kanda, T., Ishii, A.,
Ishihara, K., Serikawa, T., Yamada, J., Sasa, M.,
1994. Inhibition by topiramate of seizures in
spontaneously epileptic rats and DBA/2 mice.
Eur. J. Pharmacol., 254, 83-89.
21. Niebauer, M., Gruenthal, M., 1999. Topiramate
reduces neuronal injury after experimental stetus
epilepticus. Brain Res., 837, 263-269.
7
22. Ozawa, S., Kamiya, H., Tsuzuki, K., 1998.
Glutamate receptors in the mammalian central
nervous system. Prog. Neurobiol., 54, 581-618.
23. Rigoulot, M.A., Boehrer, A., Nehlig, A., 2003.
Effects of topiramate in two models of
genetically determined generalized epilepsy, the
GAERS and the audiogenic Wistar AS.
Epilepsia, 44, 14-19.
24. Rigoulot, M.A., Koning, E., Ferrandon, A.,
Nehlig, A., 2004. Neuroprotective properties of
topiramate in the lithium-pilocarpine model of
epilepsy.J. Pharmacol Exp. Ther., 308, 787-795.
25. Russo, E., Constanti, A., Ferreri, G., Citraro, R.,
De Sarro, G., 2004. Nifedipine effects the
anticonvulsant activity of topiramate in various
animal models of epilepsy. Neuropharmacology,
46, 865-878.
26. Sankar, R., Holmes, G.L., 2004. Mechanisms of
action for the commonly used antiepileptic drugs:
relevance to antiepileptic drug-associated
neurobehavioral adverse effects. J. Child Neurol.,
19, 6-14.
27. Shank, R.P., Gardocki, J.F., 1994. Vaught, J.L.,
Topiramate: preclinical evaluation of structurally
novel anticonvulsant. Epilepsia, 35, 450-460.
28. Soderpalm, B., 2002. Anticonvulsants: aspects of
their mechanisms of action. Eur. J. Pain, 6, 3-9.
29. Tucker, G.M., 2002. Oral anticonvulsants used in
the chronic management of seizure disorders. P&
T, 27, 96-102.
30. Wauquier, A., Zhous, S., 1996. Topiramate: a
potent anticonvulsant in the amygdala-kindled
rat. Epilepsy Res., 24, 73-77.
31. White, H.S., Brown S.D., Woodhead, J.H.,
Skeen, G.A., Wolf, H.H., 1997. Topiramate
enhances GABA mediated chloride flux and
GABA evoked chloride currents in murine brain
neurons and increases seizure threshold. Epilepsy
Res., 28, 167-179.
32. White, H.S., Brown, S.D., Woodhead, J.H.,
Skeen, G.A., Wolf, H.H., 2000. Topiramate
modulates GABA evoked current in murine
cortical neurons by a nonbenzodiazepine
mechanism. Epilepsia, 41, 17-20.
33. Zenbilci, N., 1995. Sinir Sisitemi Hastalıkları,
3.Baskı, Cerrahpaşa Tıp Fakültesi Yayınları, İstanbul,
625-661.
34. Zhang, X., Velumian, A.A., Jones, O.T., Carlen,
P.L., 2000. Modulation of high voltage activated
calcium channels in dentate granule cells by
topiramate. Epilepsia, 41, 52-60.
35. M., 1997. Topiramate attenuates voltage gated
sodium currents in rat cerebellar granule cells.
Neurosci. Lett., 231, 123-126.

Thank you for copying data from http://www.arastirmax.com